According to a new report published by Allied Market Research, titled, Potential Analysis of Human DNA Vaccines Market by Forecast Scenario: Global Opportunity Analysis and Industry Forecast, 2020-2030, the global potential analysis of human DNA vaccines market is expected to account for $3,762 million by 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030. Key opportunities for market expansion include the high need for vaccines for immunization & prevention of infectious diseases.
Access Full Summary at: https://www.alliedmarketresearch.com/potential-analysis-of-human-DNA-vaccines-market
Vaccines used currently are composed of killed pathogen or live attenuated viruses, whereas DNA vaccines consist of the DNA sequence of the antigen, which is administered in humans to stimulate an immune response. This approach offers a number of potential advantages over traditional approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent, and the relative ease of large-scale manufacture. In addition, DNA vaccines are temperature stable, leading to easier storage and transport. DNA vaccination may provide an important tool for stimulating an immune response in HBV, HCV, and HIV patients, owing to their therapeutic potential for ongoing chronic viral infection. For instance, Inovios INO-3112 is in phase II clinical trial, and can be used to treat cervical cancer caused by HPV. This immunotherapy enables the body to produce E6 and E7 antigens to induce a stronger targeted immune response against HPV-associated diseases, such as cervical cancer.
Key Findings of the Potential Analysis of Human DNA Vaccines Market:
- North America is expected to dominate the market in 2020, and is projected to grow at the highest CAGR during the forecast period.
- Europe is the second largest potential market, and is expected to grow at a CAGR of 9.0%.
The major players profiled in the global potential analysis of human DNA vaccines market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.